Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
GBI Research, the leading business intelligence provider, has released its latest research: Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -
Disease overview, as well as treatment algorithms and treatment usage patterns
Market size and forecast for the APAC breast cancer market from 2013 to 2020
Major marketed products in the APAC region along with a heat map of product performance
In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements that could have impact on growth trends
Reasons to buy
The report will enhance your decision-making capability by allowing you to -
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts business intelligence provider GBI Research.
According to the company’s latest report*, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.
Saurabh Sharma, Analyst for GBI Research, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”
These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.
Sharma continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”
From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to GBI Research.
*Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
This report analyzes treatment usage patterns, market characterization, pipeline analysis, key licensing and co-development deals in the breast cancer therapeutics market in Australia, China, India and Japan.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.